CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
FIBCAN focuses on identifying new targets for the prevention and treatment of liver cancer driven by fibrosis, particularly through the investigation of Claudin-1. The project utilizes advanced modeling techniques and patient-derived systems to develop innovative therapeutic strategies for advanced liver diseases, incl…
Advanced liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) are major challenges for global health. HCC is the second leading and fastest rising cause of cancer death worldwide.
Viral and metabolic liver disease are the main risk factors for HCC, which nearly always arises in advanced liver fibrosis.
For metabolic liver disease approved therapies are absent.
Cure or suppression of viral infection cannot eliminate the HCC risk in patients with advanced fibrosis.
Despite significa…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
THE UNIVERSITY OF TEXAS SYSTEM
United States, Austin
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
